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Methotrexate (MTX) has been established as the anchor 
drug in the treatment of rheumatoid arthritis (RA) for 
decades. Its major role as an eﬀ  ective and well-tolerated 
substance impressively demonstrates that the principle of 
folate inhibition has key anti-inﬂ  ammatory eﬀ  ects in the 
pathomechanism of arthritis. MTX enters the cell 
primarily by two ways: the reduced folate carrier (RFC) 
and the folate receptor (FR)-β. Th   e latter is the target of a 
novel, interesting approach for treating arthritis that was 
introduced in a previous issue of Arthritis Research & 
Th  erapy [1]. RFC is a transmembrane folate transport 
mechanism that has a ubiquitous distribution throughout 
the body [2,3]. Th  e high aﬃ   nity of MTX for RFC may 
explain why MTX has eﬀ  ects on a large number of cell 
types. Some are therapeutic targets, such as synovial 
lymphocytes, but others, such as organ cells of liver or 
kidney, are sensitive to toxic eﬀ  ects of MTX, thus consti-
tuting a dose-limiting factor. In contrast to RFC, FR-β has 
a restricted distribution, mainly on activated myelo-
mono  cytic cells and neutrophils [4]. In synovial tissue of 
RA patients it has been shown that FR-β is selectively 
expressed on activated monocytes and synovial macro-
phages and that MTX can enter the cell through receptor-
mediated endocytosis [5]. Th  e monocyte/macrophage 
population of the inﬂ  amed synovia is a key eﬀ  ector cell of 
inﬂ  ammation and main source of cytokines such as TNF-
alpha [6]. MTX may therefore mediate important anti-
inﬂ  am  matory  eﬀ   ects through its eﬀ   ect on synovial 
macro  phages in RA. Moreover, reduction of cardio-
vascular mortality of RA patients by MTX is also thought 
to be mediated by an eﬀ  ect on this cell lineage, as it has 
been shown that MTX reduces foam cell formation by 
lipid-laden macrophages [7].
Th  e speciﬁ  c expression of folate receptors in synovial 
tissue of RA patients has been used to develop methods 
to image activated macrophages in the rat model of 
adjuvant-induced arthritis [8]. Moreover, a recombinant 
variable-region antibody fragment (Fv) against FR-β, 
which was coupled to Pseudomonas exotoxin A (PE38), 
was shown to inhibit RA synovial macrophages in vitro
and has strong anti-inﬂ  ammatory  eﬀ   ects in a human 
SCID mouse model for RA in vivo [9]. Furthermore, 
eﬀ  orts have been taken to identify FR-β-speciﬁ  c folate 
inhibitors, which allow speciﬁ   c targeting of the FR-β 
expressing cells with no aﬃ   nity to RFC [10].
Targeting folate receptors is therefore a way of focusing 
the eﬀ  ector cell population of synovial macrophages and 
thus has potential as a speciﬁ   c treatment of synovial 
inﬂ  ammation. Lu and colleagues in this issue [1] present 
a novel FR-speciﬁ  c agent that has the potential to bring 
this approach much closer to clinical use. Th  ey use a 
novel construct, EC0746, which consists of a folate 
moiety and the molecule aminopterin (AMT), both 
connected by a saccharo-amino acid peptide spacer and a 
hydrazide/disulﬁ  de linker. AMT is a folate antagonist and 
closely related to MTX. While it has strong anti-folate 
eﬀ  ects, its use as a free drug was restricted by frequent 
toxicity, which is why it did not ﬁ  nd its way into clinical 
practice. Th   e folate moiety of EC0746 binds the conjugate 
to FR-β, thus targeting the drug to synovial macrophages 
in synovial inﬂ   ammation. While the peptide spacer 
reduces hepatic clearance during circulation of the drug, 
the chemical linker is rapidly cleaved in the endosomal 
structures when the drug conjugate is taken up into the 
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High expression of folate receptors is characteristic for 
the eff  ector cell population of synovial macrophages in 
synovial infl  ammation. A new drug conjugate, EC0746, 
targets the folate inhibitor aminopterin to folate 
receptors. In vitro studies show that this conjugate acts 
antiproliferatively and inhibits cytokine production 
by macrophage cell lines. Moreover, it shows strong 
anti-arthritic eff  ects in the rat model of adjuvant-
induced arthritis in vivo. Toxicity of aminopterin was 
reduced 40-fold by using equimolar doses of the drug 
conjugate. In conclusion, this new treatment approach 
has the potential to further improve the most 
successful principle of folate inhibition in the treatment 
of arthritis.
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EC0746 is a classic example of the application of targeted 
drug delivery, in this case the targeting of the antifolate 
(AMT) to FR-β-carrying cells. Lu and colleagues per-
formed a number of in vitro and in vivo studies that 
showed the high anti-arthritic potential of this construct. 
EC0746 has a high binding speciﬁ  city for FR-β-expressing 
cells. It acts antiproliferatively on one FR-β-expressing 
macrophage-derived cell line and blocks cytokine 
production after stimulation with lipopolysaccharide and 
interferon-γ in another. For in vivo studies, the rat model 
of adjuvant-induced arthritis was used, which is charac-
terized by a high inﬂ  ammatory response dominated by a 
strong activation of macrophages. Treatment with 
EC0746 given subcutaneously twice weekly showed a 
very good response with about 91% inhibition of paw 
edema and eﬀ  ective suppression of the systemic signs of 
the disease, such as weight loss and splenomegaly. Th  e 
eﬀ  ect was strongly superior to those of MTX and as well 
the TNF-inhibitor etanercept. Most interestingly, 
EC0746 was markedly safer than native AMT, with a 
40-fold diﬀ  erence in toxicity, which is explained by the 
fact that the conjugate is constructed to be cleaved to the 
active drug after cellular uptake only.
Treatment with EC0746 is an interesting novel approach 
that uses an FR-speciﬁ   c construct to target the folate 
inhibitor AMT to activated synovial macrophages. 
However, several questions remain: will the folate intake 
have to be restricted in clinical trials in order to prevent 
competition for FR-β? Epithelial cells carry FR-α, which 
will bind EC0745 as well. Will this result in toxicity? Th  e 
development of targeted drug delivery towards folate 
receptors for clinical use is still in its infancy. 
Nevertheless, new approaches demonstrate that targeting 
pathways of folate metabolism is still good for new 
weapons against arthritis.
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